Mesothelioma Community Will Convene to Focus on Cure - International Research Symposium Unites Patients, Advocates, Foremost Medical Experts

Sep 22, 2005, 01:00 ET from Mesothelioma Applied Research Foundation

    SANTA BARBARA, Calif., Sept. 22 /PRNewswire/ -- The urgent mission to
 improve treatments for a deadly, asbestos-related cancer will make another
 step forward, the Mesothelioma Applied Research Foundation (MARF) announced
 today, with the Second International Symposium on Malignant Mesothelioma.
     Meso is a malignant tumor that aggressively invades the linings of the
 lungs, abdomen, heart or testicles.  The need for research to develop
 effective treatments was neglected for decades.  But in the past few years,
 exciting progress has begun.  MARF, the national nonprofit whose mission is to
 eradicate meso as a life-ending disease, has organized the Symposium to review
 this progress, elucidate the latest advances, and strengthen and encourage the
 entire meso community.
     The Symposium will be held in Las Vegas at the Caesars Palace convention
 center, October 6 through 8.  Following the highly successful 2004 format, the
 program combines highly relevant material for the patient/family and advocacy
 communities with scientific presentations by leading experts on the latest in
 meso science and treatment.
     The Symposium will open powerfully with presentations on the scope of the
 mesothelioma tragedy and the continuing threat, by Dr. Stephen Levin from the
 renowned Mount Sinai Irving Selikoff Center for Occupational and Environmental
 Medicine, author and Pulitzer Prize winning journalist Andrew Schneider, and
 international experts Michael Harbut and Michele Carbone.
     Sessions focused specifically for patients and caregivers will cover the
 clinical aspects of the disease and its treatment, including surgery,
 chemotherapy, experimental treatments, and pain management.  Extended
 break-out sessions are planned for patients, caregivers and the bereaved, to
 offer holistic strategies for the emotional, physical and psychological
 aspects of the disease.
     Major scientific topics will include evolving diagnostic, prognostic and
 staging technologies, including the latest in early detection.  Multi-modal
 management -- surgery, radio and chemotherapy -- will be covered in detail for
 both pleural and peritoneal meso.  Systemic chemotherapy protocols will be
 reviewed, including an assessment of the Alimta/Cisplatin regimen.  Second
 line and novel treatment approaches will be discussed, along with a thorough
 overview of meso research projects currently underway.  Participating
 physicians will receive CME credits for these sessions.  Patients, family
 members and other non-medical professionals are also welcome to attend.
     The Symposium will also feature events to encourage and strengthen the
 meso community.  A special tribute ceremony will honor loved ones lost to the
 disease.  At the gala dinner, patients in attendance will be specially
 acknowledged; Jordan Zevon, who lost his father -- renowned American
 songwriter Warren Zevon -- to mesothelioma in 2003, will perform; MARF will
 award "Pioneer" awards to the select handful of companies that are investing
 in meso research; and the winner of MARF's annual "Congressman Bruce Vento
 Hope Builder Award" will be announced.  Last year, MARF Board of Directors
 member Susan Vento, who lost her husband Congressman Bruce Vento to meso,
 presented the award to Senator Patty Murray for her work to ban asbestos and
 provide for federal funding of meso research.
     Dr. Nicholas Vogelzang, Director  of the Nevada Cancer Institute, and Dr.
 Harvey Pass, Chief, Division of Thoracic Surgery and Thoracic Oncology at NYU,
 are contributing their vast meso expertise as the Symposium co-chairs.  The
 Symposium is also made possible by the generous financial support of Eli Lilly
 and Company; SimmonsCooper LLC; Waters & Kraus, LLP; Stanley, Mandel & Iola,
 LLP; Bergman & Frockt; The David Law Firm; Merck & Co.; Alfacell; and
 Fujirebio Diagnostics.
 
     For more information or to register for the Symposium go to www.marf.org
 or contact MARF Executive Director Chris Hahn, 805-560-8942, c-hahn@marf.org,
 or MARF Communications Director Klaus Brauch, 714-969-1481, k-brauch@marf.org.
 
 

SOURCE Mesothelioma Applied Research Foundation
    SANTA BARBARA, Calif., Sept. 22 /PRNewswire/ -- The urgent mission to
 improve treatments for a deadly, asbestos-related cancer will make another
 step forward, the Mesothelioma Applied Research Foundation (MARF) announced
 today, with the Second International Symposium on Malignant Mesothelioma.
     Meso is a malignant tumor that aggressively invades the linings of the
 lungs, abdomen, heart or testicles.  The need for research to develop
 effective treatments was neglected for decades.  But in the past few years,
 exciting progress has begun.  MARF, the national nonprofit whose mission is to
 eradicate meso as a life-ending disease, has organized the Symposium to review
 this progress, elucidate the latest advances, and strengthen and encourage the
 entire meso community.
     The Symposium will be held in Las Vegas at the Caesars Palace convention
 center, October 6 through 8.  Following the highly successful 2004 format, the
 program combines highly relevant material for the patient/family and advocacy
 communities with scientific presentations by leading experts on the latest in
 meso science and treatment.
     The Symposium will open powerfully with presentations on the scope of the
 mesothelioma tragedy and the continuing threat, by Dr. Stephen Levin from the
 renowned Mount Sinai Irving Selikoff Center for Occupational and Environmental
 Medicine, author and Pulitzer Prize winning journalist Andrew Schneider, and
 international experts Michael Harbut and Michele Carbone.
     Sessions focused specifically for patients and caregivers will cover the
 clinical aspects of the disease and its treatment, including surgery,
 chemotherapy, experimental treatments, and pain management.  Extended
 break-out sessions are planned for patients, caregivers and the bereaved, to
 offer holistic strategies for the emotional, physical and psychological
 aspects of the disease.
     Major scientific topics will include evolving diagnostic, prognostic and
 staging technologies, including the latest in early detection.  Multi-modal
 management -- surgery, radio and chemotherapy -- will be covered in detail for
 both pleural and peritoneal meso.  Systemic chemotherapy protocols will be
 reviewed, including an assessment of the Alimta/Cisplatin regimen.  Second
 line and novel treatment approaches will be discussed, along with a thorough
 overview of meso research projects currently underway.  Participating
 physicians will receive CME credits for these sessions.  Patients, family
 members and other non-medical professionals are also welcome to attend.
     The Symposium will also feature events to encourage and strengthen the
 meso community.  A special tribute ceremony will honor loved ones lost to the
 disease.  At the gala dinner, patients in attendance will be specially
 acknowledged; Jordan Zevon, who lost his father -- renowned American
 songwriter Warren Zevon -- to mesothelioma in 2003, will perform; MARF will
 award "Pioneer" awards to the select handful of companies that are investing
 in meso research; and the winner of MARF's annual "Congressman Bruce Vento
 Hope Builder Award" will be announced.  Last year, MARF Board of Directors
 member Susan Vento, who lost her husband Congressman Bruce Vento to meso,
 presented the award to Senator Patty Murray for her work to ban asbestos and
 provide for federal funding of meso research.
     Dr. Nicholas Vogelzang, Director  of the Nevada Cancer Institute, and Dr.
 Harvey Pass, Chief, Division of Thoracic Surgery and Thoracic Oncology at NYU,
 are contributing their vast meso expertise as the Symposium co-chairs.  The
 Symposium is also made possible by the generous financial support of Eli Lilly
 and Company; SimmonsCooper LLC; Waters & Kraus, LLP; Stanley, Mandel & Iola,
 LLP; Bergman & Frockt; The David Law Firm; Merck & Co.; Alfacell; and
 Fujirebio Diagnostics.
 
     For more information or to register for the Symposium go to www.marf.org
 or contact MARF Executive Director Chris Hahn, 805-560-8942, c-hahn@marf.org,
 or MARF Communications Director Klaus Brauch, 714-969-1481, k-brauch@marf.org.
 
 SOURCE  Mesothelioma Applied Research Foundation